Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Glepaglutide in Renal Impairment
NCT04178447Phase 1Completed
- Sponsor
- Zealand Pharma
- Start
- Dec 2019
- Primary completion
- Jul 2020
- Modality
- Peptides
- Countries
- 2
01
Overview
Phase 1, open-label trial of glepaglutide in short bowel syndrome (SBS) (4 arms), sponsored by Zealand Pharma. Primary endpoint: Pharmacokinetic Variables at 11 days. Started Dec 2019; status: completed.
02
Drugs
glepaglutide
03
Conditions
short bowel syndrome (SBS)
Beyond the preview
Go deeper on NCT04178447.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04178447.